ID
45756
Descrição
Principal Investigator: Daphne W. Bell, PhD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA MeSH: Endometrial Neoplasms,Carcinoma, Endometrioid https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001153 The purpose of this study was to identify somatic (tumor-specific) mutations in advanced stage endometrioid endometrial carcinoma tumor exomes. The dataset was generated at the NIH Intramural Sequencing Center (NISC) and NHGRI by next generation sequencing the exomes of 19 de-identified primary tumor DNAs, from advanced stage tumors, and matched non-tumor DNAs.
Link
Palavras-chave
Versões (1)
- 05/06/2023 05/06/2023 - Chiara Middel
Titular dos direitos
Daphne W. Bell, PhD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
Transferido a
5 de junho de 2023
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
dbGaP phs001153 Somatic Mutational Analysis by Exome Sequencing Late-Stage Endometrioid Endometrial Carcinoma
Subject ID, consent group, and affection status of participants with endometrioid endometrial carcinoma and involved in the "Somatic Mutational Analysis by Exome Sequencing Late-Stage Endometrioid Endometrial Carcinoma" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with endometrioid endometrial carcinoma and involved in the "Somatic Mutational Analysis by Exome Sequencing Late-Stage Endometrioid Endometrial Carcinoma" project.
- Sample ID, subject ID, and sample use variable obtained from participants with endometrioid endometrial carcinoma and involved in the "Somatic Mutational Analysis by Exome Sequencing Late-Stage Endometrioid Endometrial Carcinoma" project.
- Subject ID and gender of participants with endometrioid endometrial carcinoma and involved in the "Somatic Mutational Analysis by Exome Sequencing Late-Stage Endometrioid Endometrial Carcinoma" project.
- Sample ID, analyte type, body site where sample was obtained, histological type of sample, tumor status of sample, primary tumor location, primary or metastatic tumor, and sequencing center of participants with endometrioid endometrial carcinoma and involved in the "Somatic Mutational Analysis by Exome Sequencing Late-Stage Endometrioid Endometrial Carcinoma" project.
Similar models
Subject ID, consent group, and affection status of participants with endometrioid endometrial carcinoma and involved in the "Somatic Mutational Analysis by Exome Sequencing Late-Stage Endometrioid Endometrial Carcinoma" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with endometrioid endometrial carcinoma and involved in the "Somatic Mutational Analysis by Exome Sequencing Late-Stage Endometrioid Endometrial Carcinoma" project.
- Sample ID, subject ID, and sample use variable obtained from participants with endometrioid endometrial carcinoma and involved in the "Somatic Mutational Analysis by Exome Sequencing Late-Stage Endometrioid Endometrial Carcinoma" project.
- Subject ID and gender of participants with endometrioid endometrial carcinoma and involved in the "Somatic Mutational Analysis by Exome Sequencing Late-Stage Endometrioid Endometrial Carcinoma" project.
- Sample ID, analyte type, body site where sample was obtained, histological type of sample, tumor status of sample, primary tumor location, primary or metastatic tumor, and sequencing center of participants with endometrioid endometrial carcinoma and involved in the "Somatic Mutational Analysis by Exome Sequencing Late-Stage Endometrioid Endometrial Carcinoma" project.
C0441833 (UMLS CUI [1,2])